Clinical Study Of Yiqi Tongluo Jiedu Fang Decoction Combined EGFR-TKI Targeted Therapy For Non-Small Cell Lung Cancer

Objective:Used in our hospital YiQi TongLuo JieDu Decoction party of EGFR-TKI targetedtherapy in non-small cell lung cancer, and to observe the clinical curative effect, adversereactions, progression-free survival, the influence of the clinical efficient, effectivecontrol and safety. This subject mentioned in the treatment of EGFR TKIs including(Gefitinib) and it (erlotinib) two targeted drugs.The research methods:Collection in April2012-October2013of60patients eligible for inclusion criteria,were randomly divided into two groups: treatment group,30cases with YiQi TongLuoJieDu Decoction party+EGFR-TKI treatment; Control group30cases, usingsingle-agent EGFR-TKI treatment, to disease progression. Observation of60casesbefore and after the treatment, TCM syndrome score (table observed by a syndrome ofTCM hou score), quality of life score (DLQI score standard), carcinoembryonic antigenin the blood CEA difference before and after the treatment, progression-free survival,clinical efficient, effective control and the evaluation of adverse reactions. After theclinical observation, statistical data, using SPSS17.0analysis.Results:1. In the aspect of clinical effectiveness (RR) targeted therapy group andcombination group were63.33%and66.67%respectively, the disease control rates(DCR) were86.67%and90%respectively, the comparison of two groups, there were nosignificant difference significance (P>0.05).2. In TCM syndrome integral, the treatment group after treatment of TCMsyndrome total effective rate improve significantly higher than control group (p <0.05)after treatment of TCM syndrome integral treatment group than the control groupdecreased obviously, there are significant difference (p <0.05), the treatment group ofclinical syndromes of traditional Chinese medicine has a good effect.3. The major adverse reactions to skin rashes and mild diarrhea, comparison of two groups, there was no significant difference (P>0.05).4. The carcinoembryonic antigen (CEA difference before and after the treatment:there was no significant difference between the two groups (P>0.05), not statisticallysignificant.5. In terms of quality of survival, quality of life score higher than the control group,treatment group significant difference (P <0.05), is similar between the two groupshave statistical significance.6. In progression-free surial aspects: as of the last access time, the treatment groupcompared with control group, PFS were9.5months and12.4months, and the treatmentgroup of PFS extended the2.9months, there are significant differences (P <0.05), issimilar between the two groups have statistical significance. But some patients into thegroup of late, the PFS is under observation, data will further improve over time.7. Safety evaluation: before the treatment, routine blood, liver and kidney functiondifference between the two groups had no statistical significance (P>0.05); In the twogroups of blood routine, liver and kidney function before and after treatmentcomparison, there were no statistically significant difference (P>0.05).Conclusion:YiQi TongLuo JieDu Decoction party combined targeted drugs can alleviateclinical symptoms in patients with non-small cell lung cancer, improve the quality ofsurvival, and longer progression-free survival period, the party security good is aneffective method for treatment of non-small cell lung cancer.